Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations

Gambino,Gaetana; Tancredi,Mariella; Falaschi,Elisabetta; Aretini,Paolo; Caligo,Maria  Adelaide

doi:10.3892/ijmm.2015.2103

Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations

Authors:
- Gaetana Gambino
- Mariella Tancredi
- Elisabetta Falaschi
- Paolo Aretini
- Maria Adelaide Caligo
View Affiliations

Affiliations: Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa 56126, Italy, Section of Genetic Oncology, Santa Chiara University Hospital, Pisa 56126, Italy, Fondazione Pisana per la Scienza - ONLUS, Pisa 56126, Italy
Published online on: February 16, 2015 https://doi.org/10.3892/ijmm.2015.2103
Pages: 950-956
Copyright: © Gambino et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The study of BRCA1 and BRCA2 genes and their alterations has been essential to the understanding of the development of familial breast and ovarian cancers. Many of the variants identified have an unknown pathogenic significance. These include variants which determine alternative mRNA splicing, identified in the intronic regions and those are capable of destroying the splicing ability. The aim of this study was to detect BRCA1/BRCA2 aberrant transcripts resulting from alternative splicing, in women with a known family history and/or early onset of breast and/or ovarian cancer, tested wild-type for BRCA1 and BRCA2. The identification and characterization of aberrant transcripts through the analysis of mRNA levels in blood lymphocytes may help us to recognize families otherwise misclassified as wild-type BRCA1 and BRCA2. Blood samples were collected from 13 women that had a family history of breast and/or ovarian cancer and tested negative for pathogenic mutations in the BRCA1 and BRCA2 genes. Total RNA was analyzed for the presence of BRCA1 and BRCA2 naturally occuring and pathological transcripts using RT-PCR. In 2 out of the 13 samples, 2 alternative transcripts of the BRCA1 gene were identified. These were probably pathogenic as they lacked exon 17 and exon 15, respectively, giving rise to a truncated protein. In addition to these, we identified the Δ17-19 transcript in 1 patient, which gives rise to a protein with an in-frame deletion of 69 amino acids. In conclusion, this study on alternative transcripts of the BRCA1 and BRCA2 genes revealed the presence of isoforms (prevalence of 15%) in blood samples from women with breast and ovarian cancer that were probably pathogenic, that were not detected by conventional methods of mutation screening based on direct sequencing of all coding regions, intron-exons junctions and MLPA analysis.

View Figures

View References

1	Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
2	Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C and Micklem G: Identification of the breast-cancer susceptibility gene BRCA2. Nature. 378:789–792. 1995. View Article : Google Scholar : PubMed/NCBI
3	Stratton MR and Rahman N: The emerging landscape of breast cancer susceptibility. Nat Genet. 40:17–22. 2008. View Article : Google Scholar
4	Sanz DJ, Acedo A, Infante M, Durán M, Pérez-Cabornero L, Esteban-Cardeñosa E, Lastra E, Pagani F, Miner C and Velasco EA: A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res. 16:1957–1967. 2010. View Article : Google Scholar : PubMed/NCBI
5	Chatterjee S and Pal JK: Role of 5′- and 3′-untranslated regions of mRNAs in human diseases. Biol Cell. 101:251–262. 2009. View Article : Google Scholar : PubMed/NCBI
6	Farrugia DJ, Agarwal MK, Pankratz VS, et al: Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res. 68:3523–3531. 2008. View Article : Google Scholar : PubMed/NCBI
7	Walker LC, Whiley PJ, Couch FJ, et al: Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Hum Mutat. 31:E1484–E1505. 2010. View Article : Google Scholar : PubMed/NCBI
8	Cartegni L, Chew SL and Krainer AR: Listening to silence and understanding non-sense: exonic mutations that affect splicing. Nat Rev Genet. 3:285–298. 2002. View Article : Google Scholar : PubMed/NCBI
9	Spurdle AB, Couch FJ, Hogervorst FB, Radice P and Sinilnikova OM: Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat. 29:1304–1313. 2008. View Article : Google Scholar : PubMed/NCBI
10	Lu M, Conzen SD, Cole CN and Arrick BA: Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells. Cancer Res. 56:4578–4581. 1996.PubMed/NCBI
11	Wang H, Shao N, Ding QM, Cui J, Reddy ES and Rao VN: BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene. 15:143–157. 1997. View Article : Google Scholar : PubMed/NCBI
12	Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ and Calzone FJ: Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene. 14:1–16. 1997. View Article : Google Scholar : PubMed/NCBI
13	Orban TI and Olah E: Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines. Biochem Biophys Res Commun. 280:32–38. 2001. View Article : Google Scholar : PubMed/NCBI
14	Orban TI and Olah E: Emerging roles of BRCA1 alternative splicing. Mol Pathol. 56:191–197. 2003. View Article : Google Scholar : PubMed/NCBI
15	Maniccia AW, Lewis C, Begum N, et al: Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins. J Cell Physiol. 219:634–641. 2009. View Article : Google Scholar : PubMed/NCBI
16	Colombo M, Blok MJ, Whiley P, et al: Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Hum Mol Genet. 23:3666–3680. 2014. View Article : Google Scholar : PubMed/NCBI
17	Chen M and Manley JL: Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol. 10:741–754. 2009.PubMed/NCBI
18	Tesoriero AA, Wong EM, Jenkins MA, Hopper JL, Brown MA, Chenevix-Trench G, Spurdle AB and Southey MC; kConFab: Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families. Hum Mutat. 26:4952005. View Article : Google Scholar : PubMed/NCBI
19	Antoniou AC, Durocher F, Smith P, Simard J and Easton DF; INHERIT BRCAs program members: BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res. 8:R32006. View Article : Google Scholar : PubMed/NCBI
20	Antoniou AC, Cunningham AP, Peto J, et al: The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 98:1457–1466. 2008. View Article : Google Scholar : PubMed/NCBI
21	de Garibay GR, Acedo A, García-Casado Z, et al: Capillary electrophoresis analysis of conventional splicing assays: IARC analytical and clinical classification of 31BRCA2 genetic variants. Hum Mutat. 35:53–57. 2014. View Article : Google Scholar
22	Houdayer C, Caux-Moncoutier V, Krieger S, et al: Guidelines for analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat. 33:1228–1238. 2012. View Article : Google Scholar : PubMed/NCBI
23	Whiley PJ, de la Hoya M, Thomassen M, et al: Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practicein standardized clinical testing. Clin Chem. 60:341–352. 2014. View Article : Google Scholar
24	Montagna M, Santacatterina M, Torri A, Menin C, Zullato D, Chieco-Bianchi L and D’Andrea E: Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families. Oncogene. 18:4160–4165. 1999. View Article : Google Scholar : PubMed/NCBI
25	Sevcik J, Falk M, Macurek L, et al: Expression of human BRCA1Delta17-19 alternative splicing variant with a truncated BRCT domain in MCF-7 cells results in impaired assembly of DNA repair complexes and aberrant DNA damage response. Cell Signal. 25:1186–1193. 2013. View Article : Google Scholar : PubMed/NCBI
26	Mazoyer S: Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat. 25:415–422. 2005. View Article : Google Scholar : PubMed/NCBI
27	Bonnet C, Krieger S, Vezain M, et al: Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet. 45:438–446. 2008. View Article : Google Scholar : PubMed/NCBI
28	Gutiérrez-Enríquez S, Coderch V, Masas M, Balmaña J and Diez O: The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts. Breast Cancer Res Treat. 117:461–465. 2009. View Article : Google Scholar
29	Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM and Mazoyer S: The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet. 11:2805–2814. 2002. View Article : Google Scholar : PubMed/NCBI